QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content
QIAGEN has partnered with Genomics England to support the Generation Study, a groundbreaking initiative to sequence genomes of 100,000 newborns in England. The study, launched in October 2024, will screen for over 200 treatable conditions that affect approximately 3,000 babies annually in the UK.
Through its Clinical Knowledge Base, QIAGEN will be the exclusive provider of clinically relevant variant content for genes included in the point-of-care sequencing test. The company's knowledge base combines expert manual curation with machine extraction, containing biological content from more than 40 databases and has been used to analyze over 4 million NGS patient test cases globally.
The initiative aims to enable earlier diagnosis and treatment of rare conditions like Metachromatic leukodystrophy (MLD), potentially improving health outcomes for thousands of families through early intervention.
QIAGEN ha collaborato con Genomics England per sostenere il Generation Study, un'iniziativa rivoluzionaria che si propone di sequenziare i genomi di 100.000 neonati in Inghilterra. Lo studio, lanciato nell'ottobre 2024, esaminerà oltre 200 condizioni trattabili che colpiscono circa 3.000 neonati all'anno nel Regno Unito.
Attraverso la sua Clinical Knowledge Base, QIAGEN sarà il fornitore esclusivo di contenuti sui varianti clinicamente rilevanti per i geni inclusi nel test di sequenziamento point-of-care. La banca dati dell'azienda combina una curatela manuale esperta con estrazione automatica, contenendo contenuti biologici provenienti da oltre 40 banche dati ed è stata utilizzata per analizzare oltre 4 milioni di casi di test per pazienti NGS a livello globale.
L'iniziativa mira a consentire una diagnosi e un trattamento più precoci di condizioni rare come la leucodistrofia metacromatica (MLD), migliorando potenzialmente i risultati di salute per migliaia di famiglie attraverso interventi tempestivi.
QIAGEN se ha asociado con Genomics England para apoyar el Generation Study, una iniciativa innovadora para secuenciar los genomas de 100,000 recién nacidos en Inglaterra. El estudio, lanzado en octubre de 2024, examinará más de 200 condiciones tratables que afectan a aproximadamente 3,000 bebés al año en el Reino Unido.
A través de su Clinical Knowledge Base, QIAGEN será el proveedor exclusivo de contenidos de variantes clínicamente relevantes para los genes incluidos en la prueba de secuenciación point-of-care. La base de conocimiento de la empresa combina la curaduría manual de expertos con la extracción automática, conteniendo contenido biológico de más de 40 bases de datos y ha sido utilizada para analizar más de 4 millones de casos de pruebas NGS a nivel global.
La iniciativa tiene como objetivo permitir un diagnóstico y tratamiento más temprano de condiciones raras como la leucodistrofia metacromática (MLD), mejorando potencialmente los resultados de salud para miles de familias a través de intervenciones tempranas.
QIAGEN은 Genomics England와 협력하여 잉글랜드의 100,000명의 신생아의 게놈을 시퀀싱하는 혁신적인 프로젝트인 Generation Study를 지원합니다. 2024년 10월에 시작된 이 연구는 영국에서 매년 약 3,000명의 아기에 영향을 미치는 200개 이상의 치료 가능한 질환을 선별할 것입니다.
QIAGEN은 Clinical Knowledge Base를 통해 포인트 오브 케어 시퀀싱 테스트에 포함된 유전자에 대한 임상적으로 관련된 변이 콘텐츠를 독점적으로 제공합니다. 이 회사의 지식 기반은 전문 수동 큐레이션과 기계 추출을 결합하여 40개 이상의 데이터베이스에서 생물학적 콘텐츠를 포함하고 있으며, 전 세계적으로 400만 건 이상의 NGS 환자 테스트 사례를 분석하는 데 사용되었습니다.
이 이니셔티브는 메타크로마틱 백질 이영양증(MLD)과 같은 희귀 질환의 조기 진단 및 치료를 가능하게 하여 조기 개입을 통해 수천 가족의 건강 결과를 개선할 것을 목표로 합니다.
QIAGEN s'est associé à Genomics England pour soutenir l'étude Generation, une initiative révolutionnaire visant à séquencer les génomes de 100 000 nouveau-nés en Angleterre. L'étude, lancée en octobre 2024, examinera plus de 200 conditions traitables qui touchent environ 3 000 bébés chaque année au Royaume-Uni.
Grâce à sa base de connaissances cliniques, QIAGEN sera le fournisseur exclusif de contenus de variantes cliniquement pertinents pour les gènes inclus dans le test de séquençage point-of-care. La base de connaissances de l'entreprise combine la curation manuelle d'experts avec une extraction automatisée, contenant des contenus biologiques provenant de plus de 40 bases de données et a été utilisée pour analyser plus de 4 millions de cas de tests NGS à travers le monde.
L'initiative vise à permettre un diagnostic et un traitement plus précoces de conditions rares telles que la leucodystrophie métachromatique (MLD), améliorant potentiellement les résultats de santé de milliers de familles grâce à une intervention précoce.
QIAGEN hat sich mit Genomics England zusammengeschlossen, um die Generation Study zu unterstützen, eine bahnbrechende Initiative zur Sequenzierung der Genome von 100.000 Neugeborenen in England. Die Studie, die im Oktober 2024 gestartet wird, wird über 200 behandelbare Erkrankungen untersuchen, die jährlich etwa 3.000 Babys im Vereinigten Königreich betreffen.
Durch seine Clinical Knowledge Base wird QIAGEN der exklusive Anbieter von klinisch relevanten Variant-Inhalten für die in den Point-of-Care-Sequenzierungstest einbezogenen Gene sein. Die Wissensdatenbank des Unternehmens kombiniert Expertenkuration mit maschineller Extraktion, enthält biologische Inhalte aus mehr als 40 Datenbanken und wurde genutzt, um weltweit über 4 Millionen NGS-Patiententestfälle zu analysieren.
Die Initiative zielt darauf ab, eine frühere Diagnose und Behandlung seltener Erkrankungen wie der metachromatischen Leukodystrophie (MLD) zu ermöglichen, um potenziell die Gesundheitsergebnisse für Tausende von Familien durch frühzeitige Intervention zu verbessern.
- Exclusive partnership with Genomics England for a major national healthcare initiative
- Access to a significant market of 100,000 newborn genome sequences
- Demonstrated trust in QIAGEN's technology with 4 million+ NGS patient test cases analyzed globally
- None.
Insights
This collaboration between QIAGEN and Genomics England represents a groundbreaking advancement in preventive pediatric medicine. The implementation of whole-genome sequencing for 100,000 newborns to screen for 200+ treatable conditions could revolutionize early intervention strategies. The projected impact on approximately 3,000 babies annually in the UK demonstrates significant market potential.
QIAGEN's Clinical Knowledge Base's selection as the exclusive variant content provider strengthens their position in the genomic interpretation market. This validates their curated database's reliability and could lead to similar partnerships globally. The project's scale and QIAGEN's track record of analyzing 4 million NGS patient cases suggests substantial recurring revenue potential from data interpretation services.
The partnership strategically positions QIAGEN in the rapidly growing preventive healthcare sector. The addressable market is significant - considering the UK's annual birth rate of approximately 700,000, this program could establish a sustainable revenue stream from genomic screening services. The exclusivity agreement for variant interpretation demonstrates QIAGEN's competitive advantage in clinical genomics.
This initiative could serve as a blueprint for other national healthcare systems, potentially creating multiple market expansion opportunities. Early disease detection programs typically yield substantial healthcare cost savings, making similar programs attractive to other countries' health systems. The successful implementation could lead to expanded screening programs and additional revenue streams for QIAGEN's diagnostic solutions.
QIAGEN's Clinical Knowledge Base's selection for this landmark study validates their investment in expert curation and clinical evidence compilation. The platform's integration of 40+ databases and citation in 35,000+ scientific publications demonstrates its scientific credibility. The combination of manual expert curation with machine extraction creates a scalable, high-quality solution essential for large-scale genomic screening programs.
The technology's ability to pre-curate knowledge for rapid comparison with newborn DNA samples addresses a critical efficiency need in clinical genomics. This positions QIAGEN advantageously in the growing market for automated genomic interpretation tools, particularly as healthcare systems globally move toward preventive genetic screening.
-
Genomics
England select QIAGEN’s Clinical Knowledge Base to power first-of-its-kind whole-genome sequencing study for newborns -
National study will screen newborns for more than 200 treatable conditions to help identify appropriate treatments that are accessible for all in
England - Clinically relevant variant content from QIAGEN will be used to support evidence-based variant interpretation and reporting results
This first-of-its-kind initiative aims to sequence the genomes of 100,000 newborns in
Through its Clinical Knowledge Base, QIAGEN will be the only company to provide clinically relevant variant content for genes included in the point-of-care sequencing test. Now that testing has begun, this content will be used to support rapid variant interpretation and reporting of sequencing results.
The Generation Study will sequence and analyze the genomes of 100,000 newborns for a set of actionable genetic conditions that may affect their health in early years. Officially launched in October 2024, the national study will screen newborns for more than 200 treatable conditions that affect approximately 3,000 babies born each year in the
“When it comes to screening newborns to identify babies at risk for developing a rare disease, there is no room for error,” said Dominic John, Head of QIAGEN Digital Insights. “We are pleased to be the only company to partner with Genomics England in this landmark program to provide nationwide access to the power of whole-genome sequencing for newborns in the
The study will identify conditions such as Metachromatic leukodystrophy (MLD) in babies sooner and could enable hundreds to benefit from earlier diagnosis and treatment that could help slow the progression of rare conditions and even extend their lives.
“Variant interpretation is really important for the Generation Study, which aims to identify more than 200 conditions in otherwise asymptomatic babies, where symptoms might not present until later in childhood,” said Dr Ellen Thomas, Chief Medical Officer, Genomics England. “By providing expert-curated content for every gene being tested in the study, QIAGEN are supporting our ability to safely return results to participants.”
The QIAGEN Clinical Knowledge Base offers comprehensive genomic content built on expert manual curation. Rather than examining and interpreting each variant in real-time against the evidence found in the medical literature, newborn sequencing benefits greatly from pre-curated knowledge which is readily comparable to each newborn’s DNA.
For over two decades, QIAGEN has brought together the power of hundreds of physicians and bioinformatics expert curators with manual and computational methods to efficiently curate, annotate and analyze complex clinical evidence that are essential for accurate and high-quality reporting.
For the Generation Study, QIAGEN curators provided comprehensive evidence for every variant seen across the 200 conditions included in the study. This focus on human effort, review and certification is critical.
The QIAGEN Clinical Knowledge Base contains biological content from more than 40 databases that has been curated for clinical relevance. It has been used by researchers, clinicians, and pharmaceutical companies for more than 25 years, and has been cited in more than 35,000 scientific publications.
A key differentiator of the QIAGEN Clinical Knowledge Base is how it combines the unmatched accuracy and consistency of QIAGEN’s proprietary expert (MD/PhD) curation with the superior efficiency of machine extraction to efficiently identify, extract and align evidence. The approach ensures scalable, high-quality molecular intelligence that users can trust to augment their own decisions.
To date, the QIAGEN Clinical Knowledge Base has been used to analyze and interpret more than 4 million NGS patient test cases globally, making it one of the most trusted genomic content sources worldwide.
For more information about QIAGEN Clinical Knowledgebase, please visit: https://digitalinsights.qiagen.com/clinical-kb/
About QIAGEN
QIAGEN N.V., a
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the
Source: QIAGEN N.V.
Category: Corporate
1 https://www.theguardian.com/science/2022/dec/13/genome-sequencing-trial-to-test-benefits-of-identifying-genetic-diseases-at-birth, as of August 28, 2024
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107278948/en/
Investor Relations
John Gilardi +49 2103 29 11711
Domenica Martorana +49 2103 29 11244
e-mail: ir@QIAGEN.com
Public Relations
Thomas Theuringer +49 2103 29 11826
Lisa Specht +49 2103 29 14181
e-mail: pr@QIAGEN.com
Source: QIAGEN N.V.
FAQ
What is QIAGEN's role in the UK's 100,000 newborn genome sequencing study?
How many conditions will be screened in the UK Generation Study using QGEN's technology?
When did the QIAGEN-supported Generation Study launch in the UK?
How many patient test cases has QIAGEN's Clinical Knowledge Base analyzed globally?
What is the target number of newborns to be sequenced in the UK Generation Study using QGEN's technology?
